Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

NCT04504513 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Myelosuppression Adult
Chemotherapeutic Toxicity
Small Cell Lung Cancer

Interventions

DRUG: Trilaciclib

Sponsor

G1 Therapeutics, Inc.

Collaborators

[object Object]